Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

By Colleoni M.   Price K.   Castiglione-Gertsch M.   Goldhirsch A.   Coates A.   Lindtner J.   Collins J.   Gelber R.D.   Thurlimann B.   Rudenstam C.M.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1693-1700

Elsevier

Access to resources Recommend Favorite

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

By Özdemir Nuriye   Abalı Hüseyin   Öksüzoğlu Berna   Budakoglu Burçin   Uncu Doğan   Güler Tunç   Odabaşı Hatice   Zengin Nurullah  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 680-684

Humana Press, Inc

Access to resources Recommend Favorite

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

By Shayne Michelle   Crawford Jeffrey   Dale David   Culakova Eva   Lyman Gary  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 255-262

Springer Publishing Company

Access to resources Recommend Favorite

Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy

By Correa Denise   Rocco-Donovan Mary   DeAngelis Lisa   Dolgoff-Kaspar Rima   Iwamoto Fabio   Yahalom Joachim   Abrey Lauren  

Journal of Neuro-Oncology, Vol. 91, Iss. 3, 2009-02 ,pp. : 315-321

Springer Publishing Company

Access to resources Recommend Favorite

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the danish breast cancer cooperative gr

By Andersson M.   Lindegaard Madsen E.   Overgaard M.   Rose C.   Dombernowsky P.   Mouridsen H.T.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite